6.89 USD
+0.43 (+6.66%)
Taking everything into account, KZIA scores 1 out of 10 in our fundamental rating. KZIA was compared to 530 industry peers in the Biotechnology industry. KZIA has a bad profitability rating. Also its financial health evaluation is rather negative. KZIA is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year KZIA has reported negative net income.
KZIA had a negative operating cash flow in the past year.
In the past 5 years KZIA always reported negative net income.
KZIA had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of KZIA (-158.60%) is worse than 85.28% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -158.6% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-179.5%
ROA(5y)-124.54%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
KZIA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
Compared to 1 year ago, KZIA has more shares outstanding
The number of shares outstanding for KZIA has been increased compared to 5 years ago.
The debt/assets ratio for KZIA is higher compared to a year ago.
2.2 Solvency
KZIA has an Altman-Z score of -15.25. This is a bad value and indicates that KZIA is not financially healthy and even has some risk of bankruptcy.
KZIA has a Altman-Z score of -15.25. This is in the lower half of the industry: KZIA underperforms 78.87% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -15.25 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 0.21 indicates that KZIA may have some problems paying its short term obligations.
KZIA has a Current ratio of 0.21. This is amonst the worse of the industry: KZIA underperforms 92.83% of its industry peers.
A Quick Ratio of 0.21 indicates that KZIA may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.21, KZIA is doing worse than 92.64% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.21 | ||
| Quick Ratio | 0.21 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 93.01% over the past year.
KZIA shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -95.09%.
Measured over the past years, KZIA shows a quite strong growth in Revenue. The Revenue has been growing by 11.58% on average per year.
EPS 1Y (TTM)93.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.76%
Revenue 1Y (TTM)-95.09%
Revenue growth 3Y278.64%
Revenue growth 5Y11.58%
Sales Q2Q%-98.18%
3.2 Future
Based on estimates for the next years, KZIA will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.17% on average per year.
Based on estimates for the next years, KZIA will show a very strong growth in Revenue. The Revenue will grow by 378.99% on average per year.
EPS Next Y64.71%
EPS Next 2Y35.4%
EPS Next 3Y22.59%
EPS Next 5Y15.17%
Revenue Next Year-25.37%
Revenue Next 2Y-32.53%
Revenue Next 3Y144.27%
Revenue Next 5Y378.99%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
KZIA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for KZIA. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as KZIA's earnings are expected to grow with 22.59% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.4%
EPS Next 3Y22.59%
5. Dividend
5.1 Amount
No dividends for KZIA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NASDAQ:KZIA (12/31/2025, 8:11:35 PM)
6.89
+0.43 (+6.66%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners11.19%
Inst Owner Change9.73%
Ins Owners8.91%
Ins Owner ChangeN/A
Market Cap11.51M
Revenue(TTM)114.00K
Net Income(TTM)-28.41M
Analysts82.5
Price Target19.38 (181.28%)
Short Float %12.3%
Short Ratio0.05
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)15.15%
PT rev (3m)35.71%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)16.96%
EPS NY rev (3m)90.75%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 7.35 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-14.03
EYN/A
EPS(NY)-0.8
Fwd EYN/A
FCF(TTM)-4.67
FCFYN/A
OCF(TTM)-4.67
OCFYN/A
SpS0.94
BVpS-1.52
TBVpS-7.31
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -158.6% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-179.5%
ROA(5y)-124.54%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.13
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.21 | ||
| Quick Ratio | 0.21 | ||
| Altman-Z | -15.25 |
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)93.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.76%
EPS Next Y64.71%
EPS Next 2Y35.4%
EPS Next 3Y22.59%
EPS Next 5Y15.17%
Revenue 1Y (TTM)-95.09%
Revenue growth 3Y278.64%
Revenue growth 5Y11.58%
Sales Q2Q%-98.18%
Revenue Next Year-25.37%
Revenue Next 2Y-32.53%
Revenue Next 3Y144.27%
Revenue Next 5Y378.99%
EBIT growth 1Y-55.26%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y8.03%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y8.03%
OCF growth 3YN/A
OCF growth 5YN/A
KAZIA THERAPEUTICS-SPON ADR / KZIA FAQ
What is the fundamental rating for KZIA stock?
ChartMill assigns a fundamental rating of 1 / 10 to KZIA.
What is the valuation status for KZIA stock?
ChartMill assigns a valuation rating of 1 / 10 to KAZIA THERAPEUTICS-SPON ADR (KZIA). This can be considered as Overvalued.
Can you provide the profitability details for KAZIA THERAPEUTICS-SPON ADR?
KAZIA THERAPEUTICS-SPON ADR (KZIA) has a profitability rating of 0 / 10.
How financially healthy is KAZIA THERAPEUTICS-SPON ADR?
The financial health rating of KAZIA THERAPEUTICS-SPON ADR (KZIA) is 0 / 10.
What is the earnings growth outlook for KAZIA THERAPEUTICS-SPON ADR?
The Earnings per Share (EPS) of KAZIA THERAPEUTICS-SPON ADR (KZIA) is expected to grow by 64.71% in the next year.